Skip to content
LatchBio logo — Agent Infrastructure for Biology

LatchBio

Agent Infrastructure for Biology

Founded 2021 United States San Francisco, United States 79 employees Series B Total: $163.00M Biotechnology

General Information

Company Name LatchBio
Founded Year 2021
Location United States San Francisco, United States
Employees 79
Industries Biotechnology
Funding Stage Series B
Business Model B2B, PaaS, Platform
Revenue Model Usage Based, Subscription, Service Fee
Hiring 12 roles posted in the month to 8 Nov 2026
Offices as of Nov 2026
San Francisco, United States
Social

BounceWatch is an independent company data service, not affiliated with LatchBio. To contact LatchBio, visit latch.bio.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does LatchBio compare?

A PDF of LatchBio and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting LatchBio soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

Recorded by Bounce Watch from public sources. Every entry below carries the date we observed it, and when we have not looked recently the page says so rather than leaving silence to imply nothing happened.

Homepage Update

Significant changes detected on company website (98% content change).

Actively Hiring Nov 06, 2026

Hiring for 12 positions in the last 30 days.

AI Insight

Bounce Watch AI
5 days ago

Following a substantial Series B funding round in April 2026, LatchBio is exhibiting clear signals of strategic growth and operational expansion. The significant website overhaul (98.02% change) suggests a potential re-branding, product evolution, or preparation for a major market push, while active hiring for 12 positions confirms the company is leveraging its new capital to scale its team and capabilities. These synchronized moves indicate a concerted effort to accelerate development and solidify its market position as agent infrastructure for biology.

Signal Types
Hiring Product Update
Strategic Labels
Post-Funding Expansion Product Evolution Talent Acquisition
Next Move: Expansion
·
Impact: 8/10
·
Ideal For: Growth Equity Investors — Series B/C

About LatchBio

LatchBio, founded in 2021, has quickly carved a niche in the Biotechnology sector with its innovative slogan, "Agent Infrastructure for Biology." Headquartered in the United States, it provides integrated agent infrastructure bundled with kits and machines, effectively serving over 300 pharma, biotech, and academic teams worldwide.

In a notable show of confidence from investors, LatchBio recently secured a substantial $130.00M Series B investment on 01 April 2026. This investment highlights both the promising growth trajectory of the company and the market's strong belief in its ability to innovate and expand within a highly competitive industry.

Business keywords: agent infrastructure, biology, pharmaceutical industry, academic research, equipment manufacturing, laboratory kits, scientific machines, R&D support, life sciences, global market

Services & Products

Data Analysis and Visualization
Customizable Analysis Portal
Workflow Orchestration
Scalable Computing Solutions

Target Customers

Bioinformaticians Computational Biologists R&D Labs Biopharmaceutical Companies Solution Providers

Funding Rounds & Investors (4)

View All
Funding Stage Amount Investors Lead Investors Date
Series B $130.00M -
01 Apr 2026
Series A $28.00M 6
Lux Capital, Caffeinated Capital +4
01 Jun 2022
Seed $5.00M 5
Lux Capital, Fifty Years +3
01 Oct 2021
Seed Undisclosed 1
Swift Ventures
01 Jun 2021

LatchBio Alternatives & Competitors

View All Alternatives
LatchBio vs
Potato
Potato United States

AI scientists for closed-loop, autonomous science. We build AI agents that design, analyze, and run...

Seed
81 employees
AI, Biotechnology
LatchBio vs
Antibodies.com
Antibodies.com United Kingdom

High-quality antibodies, proteins, and ELISA kits at cost-effective prices. Discover more, for less.

Seed
9 employees
Biotechnology, Life Sciences
LatchBio vs
Automata
Automata United Kingdom

Where legacy ends, Automata begins.

Series C
167 employees
AI, Biotechnology

FAQ About LatchBio

Agent Infrastructure for Biology
LatchBio was founded in 2021.
LatchBio is headquartered in San Francisco, United States.
LatchBio operates in Biotechnology. Its work centres on agent infrastructure, biology, pharmaceutical industry and academic research. Its customers include Bioinformaticians, Computational Biologists and R&D Labs.
LatchBio has a B2B, PaaS and Platform business model. Its revenue comes from Usage Based, Subscription and Service Fee.
LatchBio has approximately 79 employees.
LatchBio has completed 4 funding rounds, raising a total of $163.00M. The latest funding stage is Series B.
LatchBio offers: Data Analysis and Visualization, Customizable Analysis Portal, Workflow Orchestration, Scalable Computing Solutions.
Top alternatives and competitors to LatchBio include Potato, Antibodies.com, Automata, antibodies-online.com, Diagnostics Biochem Canada (DBC). These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
LatchBio and Potato are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for LatchBio, https://www.bouncewatch.com/company/latchbio, updated 8 November 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout